Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2025-01-03T16:33:26.903Z Has data issue: false hasContentIssue false
  • English
  • Français

Psychotropic drugs and taxonomic systems1

Published online by Cambridge University Press:  09 July 2009

Michael Shepherd
Michael Shepherd*
Affiliation:
Institute of Psychiatry, University of London
*
2Address for correspondence: Professor Michael Shepherd, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF.
Get access Rights & Permissions [Opens in a new window]

Synopsis

Attempts to underpin the classification of psychiatric drugs in biological and clinical terms are discussed with reference to their value and limitations. The current need for a multiplative, heuristic taxonomy is suggested.

Type
Research Article
Information
Psychological Medicine , Volume 10 , Issue 1 , February 1980 , pp. 25 - 33
Copyright
Copyright © Cambridge University Press 1980

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

1

Based on a paper delivered at the 11th Congress of the Collegium Internationale Neuro-Psychopharmacologium (Vienna, 1978) and the 1st Edwin Gildea Memorial Lecture (St Louis, Missouri, 1978).

References

Bobon, D. P. (1973). Classifications and terminology of psychotropic drugs. Pharmakopsychiatrie 6, 1–12.CrossRefGoogle ScholarPubMed
Bobon, D. P. & Gottfries, C. G. (1974). The Liège physiognomy of neuroleptics, with special reference to thioxanthenes. Acta Psychiatrica Belgica 74 (5), 535–544.Google ScholarPubMed
Bobon, J. (1970). Foreword. In The Neuroleptics (ed. Bobon, D. P., Janssen, P. A. J. and Bobon, J.), p. viii. Karger: Basel.Google Scholar
Bruner, J. S. (1957). On perceptual readiness. Psychological Review 64, 123–152.CrossRefGoogle ScholarPubMed
Carlsson, A. (1977). Does dopamine play a role in schizophrenia? Psychological Medicine 7, 583–597.CrossRefGoogle ScholarPubMed
Collard, J. (1974). The main clinical classifications of neuroleptics. Acta Psychiatrica Belgica 74 (5), 462–469.Google ScholarPubMed
Creese, I., Burt, D. R. & Snyder, S. H. (1976 a). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481–483.CrossRefGoogle ScholarPubMed
Creese, I., Burt, D. R. & Snyder, S. H. (1976 b). Dopamine receptors and average clinical doses. Science 194, 546.CrossRefGoogle ScholarPubMed
Deniker, P. (1966). In La Psychopharmacologie. Presses Universitaires de France: Paris.Google Scholar
Foskett, D. J. (1971). Problems of indexing and classification in the social sciences. International Social Science Journal 23 (2), 244–255.Google Scholar
Gaddum, J. H. (1943). Biological aspects: the antagonism of drugs. Transactions of the Faraday Society 39, 323–331.CrossRefGoogle Scholar
Gaddum, J. H. (1961). Antagonism between drugs. In Neuropsychopharmacology, Vol. 2 (ed. Rothlin, E.), pp. 19–24. Elsevier: Amsterdam.Google Scholar
Gregg, J. R. (1954). The Language of Taxonomy. Columbia University Press: New York.CrossRefGoogle Scholar
Helling, M. (1976). Experience with World Health Organization. In Clinical Pharmacy and Clinical Pharmacology (ed. Gouveia, W. A., Tognoni, G. and van der Kleijn, E.), pp. 141–151. North-Holland Publishing Company: Amsterdam.Google Scholar
Helling, M. & Venulet, J. (1974). Drug recording and classification by the WHO Research Centre for International Monitoring of Adverse Reactions to Drugs. Methods of Information in Medicine 13 (3), 169–178.Google ScholarPubMed
Hempel, C. (1961). Introduction to problems of taxonomy. In Field Studies in the Mental Disorders (ed. Zubin, J.), pp. 3–22. Grune & Stratton: New York.Google Scholar
Inhelder, B. & Piaget, J. (1964). The Early Growth of Logic in the Child: Classification and Seriation. Routledge & Kegan Paul: London.Google Scholar
Iversen, L. L., Iversen, S. D. & Snyder, S. H. (eds.) (1978). Preface. In Neuroleptics and Schizophrenia, p. vii. Plenum Press: New York.Google Scholar
Jacobsen, E. (1959). The comparative pharmacology of some psychotropic drugs. Bulletin of the WHO 21, 411–493.Google ScholarPubMed
Janowski, D. S., Segal, D. S., Abrams, A., Bloom, F. & Guillemin, R. (1977). Negative naloxone effects in schizophrenic patients. Psychopharmacologia 53, 295–297.CrossRefGoogle Scholar
Janssen, P. A. J. (1970). Chemical and pharmacological classification of neuroleptics. In The Neuroleptics (ed. Bobon, D. P., Janssen, P. A. J. and Bobon, J.), pp. 33–44. Karger: Basel.Google ScholarPubMed
Johnstone, E. C., Crow, T. J., Frith, C. D., Carney, M. W. P. & Price, J. S. (1978). Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet i, 848–851.CrossRefGoogle Scholar
Kline, N. S. (1969). Nomenclature versus nature. International Journal of Psychiatry 7, 292–293.Google Scholar
Meltzer, H. L. (1976). Dopamine receptors and average clinical doses. Science 194, 545–546.CrossRefGoogle ScholarPubMed
Paton, W. D. M. (1970). Receptors as defined by their pharmacological properties. In Molecular Properties of Drug Receptors (ed. Porter, R. and O'Connor, M.), pp. 3–30. Churchill: London.Google ScholarPubMed
Perrin, C. L. (1974). Testing of computer-assisted methods for classification of pharmacological activity. Science 183, 151–152.CrossRefGoogle ScholarPubMed
Pletscher, A. & Kyburz, E. (1976). Neuroleptic drugs. Chemical versus biochemical classification. In Schizophrenia Today (D. Kemali, G. Bartholini and D. Richter), pp. 183–200. Pergamon Press: Oxford.CrossRefGoogle Scholar
Quinton, A. (1978). The Nature of Things, p. 263. Routledge & Kegan Paul: London.Google Scholar
Roberts, E. & Amacher, P. (eds.) (1978). Propranolol and Schizophrenia. Alan R. Liss, Inc.: New York.Google Scholar
Seeman, P. & Lee, T. (1974). The dopamine-releasing actions of neuroleptics and ethanol. Journal of Pharmacology and Experimental Therapeutics 190, 131–140.Google ScholarPubMed
Seeman, P. & Lee, T. (1975). Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188, 1217–1219.CrossRefGoogle ScholarPubMed
Shepherd, M. (1972). The classification of psychotropic drugs. Psychological Medicine 2, 96–110.CrossRefGoogle ScholarPubMed
Shepherd, M. (1976). Definition, classification and nomenclature: a clinical overview. In Schizophrenia Today (ed. Kemali, D., Bartholini, G. and Richter, D.), pp. 3–12. Pergamon Press: Oxford.CrossRefGoogle Scholar
Snyder, S. H. (1973). Amphetamine psychosis: a ‘model’ schizophrenia mediated by catecholamines. American Journal of Psychiatry 130, 61–67.CrossRefGoogle Scholar
Stuper, A. J. & Jurs, P. C. (1975). Classification of psychotropic drugs as sedatives or tranquillizers using pattern recognition techniques. Journal of the American Chemical Society 97 (1), 182–187.CrossRefGoogle ScholarPubMed
Thuillier, J. E. (1959). Classification of psychotropic drugs. In Psychopharmacology Frontiers (ed. Kline, N. S.), pp. 241–244. Little & Brown: Boston.Google Scholar
Ting, K. L., Lee, R. C. T., Milne, G. W. A., Shapiro, M. & Guarino, A. M. (1973). Applications of artificial intelligence: relationships between mass spectra and pharmacological activity of drugs. Science 180, 417–420.CrossRefGoogle ScholarPubMed
Toman, J. E. P. (1962). Neurotropic drugs. In Neurochemistry (ed Elliott, K. A. C., Page, I. H. and Quastel, J. H.), pp. 728–765. C. C. Thomas: Springfield, Ill.Google Scholar
World Health Organization (1967). Research in Psychopharmacology. Technical Reports Series 371. WHO: Geneva.Google Scholar
World Health Organization (1978). Manual of the International Statistical Classification of Diseases, Vol. 1, Injuries and Causes of Death. WHO: Geneva.Google Scholar